Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study by unknown
RESEARCH Open Access
Markers of increased atherosclerotic risk in
patients with chronic kidney disease: a
preliminary study
Anna Gluba-Brzózka1,6*, Marta Michalska-Kasiczak2, Beata Franczyk1, Marek Nocuń3, Peter P. Toth4,5,
Maciej Banach2,6 and Jacek Rysz1,6
Abstract
Background: The prevalence of chronic kidney disease is rising continuously. Cardiovascular disease is among
leading causes of death and premature mortality of patients with chronic kidney disease. Even the earliest stages of
chronic kidney disease are associated with higher risk of subsequent coronary heart disease. The aim of this study
was to determine markers of increased risk of atherosclerosis in CKD.
Methods: The study group consisted of a total of 80 patients (20 patients with stage I/II CKD, 20 with stage III CKD,
20 stage IV CKD and 20 stage V/dialysis) and 24 healthy volunteers. Levels of proteins (osteoprotegerin,
osteopontin, osteocalcin, matrix γ-carboxyglutamic acid protein, fetuin A, MMP-2, MMP-9, TIMP-1, TIMP-2) and
biochemical parameters were measured to analyse their influence on atherosclerosis risk in CKD patients. Cardiac
echocardiography was performed to assess structural integrity and function, presence of left ventricular hypertrophy
and systolic and diastolic function dysfunction.
Results: This study shows that the prevalence of ventricular hypertrophy (95.3 %) and diastolic dysfunction (93.2 %)
in CKD patients is high. Also E/E’ ratio was significantly higher (13.6 ± 4.4, p = 0.001), tricuspid insufficiency (27.3 in
CKD I/II vs. 71.4 in CKD V, p = 0.016), contractile dysfunction (33.3 in CKD I/II vs. 78.9 in CKD V, p = 0.040), mitral
valve calcification (0 in CKD I/II vs. 28.6 in CKD V, p = 0.044) and aortic valve calcification (0 in CKD I/II vs. 61.9 in
CKD V, p = 0.0008) were significantly more frequent in patients with CKD stage V/dialysis than in other groups. Only
MMP-2, MMP-2/TIMP-2 ratio and TIMP-1 differed significantly between groups.
Conclusions: This study shows high prevalence of ventricular hypertrophy and diastolic dysfunction in CKD
patients. Contractile dysfunction, mitral and aortic valve calcification in HD patients were significantly more frequent
than in patients with other CKD stages. Significantly increased levels of MMP-2, MMP-2/TIMP-2 ratio and lower
TIMP-1 suggests that these factors may be involved in the pathogenesis of atherosclerosis in CKD patients.
Background
Chronic kidney disease (CKD) is defined by KDIGO in
Clinical Practice Guideline for the Evaluation and Man-
agement of Chronic Kidney Disease published in 2013 as
abnormalities of kidney structure or function, present
for over 3 months, with implications for health and
CKD is classified based on cause, GFR category, and al-
buminuria category (CGA) [1]. The prevalence of
chronic kidney disease is rising continuously. According
to National Kidney Foundation (NKF) KDOQI guide-
lines, chronic kidney disease, irrespective of diagnosis, is
associated with increased risk of cardiovascular disease
(CAD), including coronary heart disease, cerebrovascular
disease, peripheral vascular disease, and heart failure,
due to both ‘traditional’ (defined in the Framingham
Heart Study) and ‘chronic kidney disease related’ CAD
risk factors, and, thus, these patients have risk on par
with the highest CAD risk group [2]. The prevalence of
uraemia-related (non-traditional) factors increases along
with the decline in kidney function. Cardiovascular dis-
ease is one of the leading causes of death and premature
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mortality of patients with chronic kidney disease. Ac-
cording to recent studies, even the earliest stages of
chronic kidney disease are associated with higher risk of
subsequent coronary heart disease [3, 4]. It has been
suggested that the assessment of CKD-associated CAD
risk factors together with conventional risk factors
should be performed in order to improve the prediction
of coronary heart disease risk [2]. Moreover, patients
with manifestations of cardiovascular disease should be
screened for evidence of kidney disease [3, 5, 6]. The re-
duction in risk factors seems to be effective in lowering
cardiovascular morbidity and mortality in patients with
CKD [2]. According to the report of NKF Task Force on
Cardiovascular Disease in Chronic Renal Disease, the
mortality due to CVD was 10 to 30 times higher in dia-
lysis patients than in the general population despite
stratification for sex, race, and the presence of diabetes
[7]. CVD mortality in dialysis patients remained ~5-fold
higher than in the general population after stratification
for age [8]. In patients with CKD the prevalence of ar-
teriosclerosis (remodelling of large arteries) and cardio-
myopathy is higher than in general population [9]. A
high prevalence of a proinflammatory state, endothelial
dysfunction, hypertension, and dyslipidemia associated
with renal disease may explain the acceleration of ath-
erosclerosis with a high prevalence of coronary ischemia
and CV events in CKD. However, the exact mechanisms
of atherosclerotic and arteriosclerotic changes in the set-
ting of CKD formation are not yet fully characterized.
Aim
The aim of this study was to determine markers of in-
creased risk of atherosclerosis in CKD.
Methods
The study group consisted of a total of 80 patients (20
patients with stage I/II CKD, 20 with stage III CKD, 20
stage IV CKD and 20 stage V/dialysis) hospitalized in
the Department of Nephrology, Hypertension and
Family Medicine. The control group consisted of 24 vol-
unteers without CKD, recruited among patients hospital-
ized due to causes other than CAD, tumours or diabetes
mellitus. All persons involved in this study signed
informed a consent form before the collection of blood
samples. The purpose and methodology of this study
was approved by the Bioethics Committee of the Med-
ical University of Lodz (no. RNN/79/12/KB). Total
cholesterol, low-density lipoprotein (LDL), high-density
lipoprotein (HDL), triglyceride (TG), albuminuria, serum
calcium and phosphate, Fe, total iron-binding capacity
(TIBC), C-reactive protein (CRP), alkaline phosphatase
activity, creatinine, urea, uric acid, total protein, the level
of fibrinogen and D-dimer were also determined. In
addition, cardiac echocardiography was performed to
assess structural integrity and function, the presence of
left ventricular hypertrophy and systolic and diastolic
function dysfunction. Contractility disorder was diag-
nosed when ejection fraction (EF) is below 44 %. The E/
A is defined as a ratio of the early (E) to late (A) ven-
tricular filling velocities, while E/E’ is a ratio of early fill-
ing (E) and early diastolic mitral annular velocity (E’)
[10]. The levels of studied proteins and biochemical
markers were analysed in blood of all people involved in
the study. The study excluded patients with diagnosed
cancer and advanced cardiovascular disease. In the
present study, concentrations of proteins involved in the
processes of vessel wall calcification and bone
metabolism disorders (osteoprotegerin [TECOMedical,
no. 8034], osteopontin [RayBiotech, ELH-OPN-001],
osteocalcin [TECOMedical, no. 8002], matrix γ-
carboxyglutamic acid protein (MGP) [USCN Life
Science, E91477Hu], fetuin A [TECOMedical, no. KT-
800]) and vascular remodelling (MMP-2, MMP-9,
TIMP-1, TIMP-2 [Raybiotech: ELH-MMP2-001, ELH-
MMP9-001, ELH-TIMP1-001, ELH-TIMP2-001]) were
measured in order to analyse their influence on athero-
sclerosis risk in CKD patients. Levels of these proteins
were determined by the ELISA method according to the
manufacturer’s instructions. Estimated glomerular filtra-
tion rate (GFR-MDRD) was calculated using the Modifi-
cation of Diet in Renal Disease:
GFR (ml/min/1.73 m2) = 186 x (Creat/88.4)−
1.154x (Age)− 0.203x (0.742 if female) x (1.210 if black),
and the classification into CKD stage confirmed using
the CKD-EPI equation:
GFR ¼ 141 x min Scr=κor 1ð Þαx max Scr=κor 1ð Þ−1:209
x 0:993Agex 1:018 if femaleð Þ
x 1:159 if blackð Þ;
where:
Scr - serum creatinine (mg/dL), κ - 0.7 for females and
0.9 for males, α is -0.329 for females and -0.411 for
males [74].
Creatinine level was measured with enzymatic
method.
This work was funded by Iuventus Plus 2010 grant no.
IP2010009870 from the Polish Ministry of Science and
Higher Education.
Statistical analysis
Results were expressed as mean with standard deviation
(mean ± SD) for continuous variables with normal distri-
bution or as a median with interquartile range (median,
25 %-75 %) in all other cases. Categorical variables are
presented as percentages related to the size of the study
group. Shapiro-Wilk test was used to verify normal dis-
tribution of variables and Levene test to analyse the
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homogeneity of variance. Standard Student t test was
used for the comparison of data showing no departures
from normality and for multiple comparisons (more
than two groups) one-way ANOVA with post hoc
Scheffe tests was used. If at least one of the aforemen-
tioned criteria is not met, non-parametric Mann–Whit-
ney U test and detailed or non-parametric analysis of
variance (Kruskal-Wallis test) with post hoc Connover-
Inman tests was used, respectively. The χ2 test of inde-
pendence was used for the analysis of discontinuous var-
iables. The analysis of logistic regression was used for
the analysis of relationship between the occurrence of
cardiovascular disorders and CKD, age, sex, and the con-
centration of selected proteins. All the echocardio-
graphic images were analysed by the single investigator
and repeated in order to assess the intra-observer vari-
ability. Intra-observer variability of echocardiographic
parameters was determined on the basis of the intra-
class correlation coefficient (ICC) with 95 % CI. A value
of p < 0.05 was considered significant. Calculations were
made with the use of statistical R program [11].
Results
Eighty patients in the study group with the average age
of 67.2 ± 11.7 and 24 patients in control group with the
age of 61.2 ± 9.6 (P = 0.042) were involved in the study.
There were 45 men and 35 women (56.2 % and 43.8 %,
respectively) in the study group and 7 men and 17
women (29.2 % and 70.8 %) in the control group (P =
0.01). Hypertension occurred significantly more often in
the study group (88.3 % vs. 37.5 %, p < 0.0001).
The analysis of biochemical parameters in both groups
revealed in patients with CKD stages I-V statistically
lower concentration of Na+ (137.9 ± 3.4 vs. 140.1 ± 2.8,
P = 0.006), haemoglobin level (11.7 ± 1.9 vs. 12.8 ± 1.4,
P <0.01), iron (12.1 ± 5.6 vs. 18.1 ± 7.0, P = 0.001), and
higher level of hsCRP (14.7 ± 30.7 vs. 3.9 ± 6.6, P <
0.005), inorganic phosphate (1.36 ± 0.44 vs. 1.14 ± 0.15,
P = 0.001), and triglycerides (1.88 ± 1.07 vs. 1.46 ± 0.62,
P = 0.02), in comparison with the control group. More-
over, in the study group, levels of markers of renal func-
tion, such as urea (14.0 ± 8.4 vs. 5.5 ± 1.9, P <0.0001),
creatinine (276.2 ± 217.4 vs. 80.1 ± 11.3, P <0.0001) and
uric acid (386.7 ± 135.9 vs. 271.7 ± 53.0, P <0.0001) were
also significantly increased. In patients with chronic kid-
ney disease, GFR-MDRD was significantly lower in com-
parison to the control group (35.0 ± 24.5 vs. 86.4 ±
16.4). The prevalence of comorbidities and frequency of
used drugs differed significantly between control and
study groups. Baseline characteristics of enrolled pa-
tients is summarized in Table 1.
Echocardiographic examination results are summa-
rized in Table 2.
All the echocardiographic measurements were per-
formed by the same person. The intra-observer variabil-
ity by ICC (interclass correlation coefficient) varied from
0.82 to 0.96. Echocardiographic examination revealed
significant differences only in the occurrence of mitral
valve fibrosis and aortic valve calcification between the
Table 1 Baseline characteristics of enrolled patients
Table 1 CKD Stages I-V Control group p
N=80 N=24
Age 67.2 ± 11.7 61.2 ± 9.6 0.042
Gender (males %) 56.2% 29.2% 0.01
Diabetes mellitus 33.3% 0% 0.0022
Atrial fibrillation 20.83% 13.79% NS
Hypertension 88.3% 37.5% <0.0001
Lipid disorders 30.6% 41.4% 0.039
Heart failure 63.9% 0% <0.0001
Hypertensive nephropathy 5.6% 0% NS
Diabetic nephropathy 4.2% 0% NS
Beta-blockers 61% 20,8% <0.007
CA-blockers 40.5% 8.3% 0.004
ACE inhibitors 69.6% 41% 0.011
Diuretics 90.5% 16.7% <0.0001
Statins 97.5% 43% <0.0001
Erythropoietina 5.6%a 0% <0.0001
Mean dialysis vintage [months]a 27±9a 0 <0.0001
a applies only to CKD stage V patients
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study and control groups. More significant differences in
echocardiographic results were observed when each
CKD stage was analysed separately. The results of this
analysis are presented below, in Table 3.
This analysis revealed significant differences in E/E’,
presence of contractility disorders, occurrence of mitral
and aortic valve calcifications and tricuspid insufficiency.
Our analysis of the relationship between selected pro-
teins and CKD stage are demonstrated in Table 4.
The analysis of the concentrations of proteins associ-
ated with bone metabolism (fetuin A, osteocalcin, osteo-
pontin, osteoprotegerin and MPG) revealed no
statistically significant differences between the control
group and patients with chronic renal failure. It was ob-
served that the concentration of osteocalcin was highest
in patients with stage I/II CKD and gradually decreased
to its lowest value in patients with stage V/dialysis. Simi-
lar proportional decreases through CKD stages were ob-
served with osteocalcin and MPG. Osteoprotegerin
concentration was lowest in subjects with stage I/II
CKD and gradually increased to reach its highest value
in patients with stage V/dialysis. However, these trends
were not statistically significant which may be related to
the small size of each group.
Statistically higher levels of MMP-2 in patients with
chronic kidney disease are observed as compared to the
control group (p = 0.002) were observed in this study
(Table 4). The lowest concentration of MMP-2 was seen
in patients with CKD stage I/II and the highest in pa-
tients with stage IV and in those on dialysis. Significant
differences in serum concentrations of metalloproteinase
inhibitor TIMP-1 (p = 0.002) and MMP-2/TIMP-2 ratio
were also observed. Statistically significant results of
multivariable analysis are presented in Table 5.
In this analysis, the presence of heart failure was asso-
ciated with the presence of chronic kidney disease, the
level of osteopontin, age, MMP-2 and AIP and this rela-
tionship was independent of osteocalcin, osteoproteg-
erin, fetuin, gender, MMP-9, TIMP-1, TIMP-2, MGP,
ANGII, ABCA1, ABCG1, non-HDL cholesterol and
urea).
There was also relationship between phosphates above
normal level and osteoprotegerin. Moreover, the pres-
ence of hypertension was associated with chronic kidney
disease, the presence of atherosclerosis associated only
with gender, while lipid disorders with non-HDL choles-
terol, AIP (high risk) and total cholesterol. An analysis
of the relationship between protein concentrations and
various biochemical markers was also performed. Statis-
tically significant results of this analysis are presented in
Table 6.
Table 2 The summary of echocardiographic examination results
Table 2 Control group CKD Stages I-V p
N=24 N=80
E/A 0.8 (0.65-1.1) 0.9 (0.8-1.2) NS
E/E’ 7.5±2.1 9.9±4.7 NS
Hypertrophy [%] 52 95.3 NS
Diastolic dysfunction [%] 29 93.2 NS
Contractility dysfunction [%] 57.1 52.8 NS
Stenosis 0 3.2 NS
Mitral valve fibrosis 53.3 81.3 P<0.01
Aortic valve fibrosis 0 14.1 NS
Mitral valve calcification 13.3 14.1 NS
Aortic valve calcification 0 30.2 P<0.02
IM 46.7 63.1 NS
IA 0 6.7 NS
IT 16.7 43.8 NS
Abbreviations used in Table 1: IM mitral insufficiency, IA atrial insufficiency, IT
tricuspid insufficiency, NS not significant
Table 3 The summary of echocardiographic examination results of patients divided into CKD stage groups
Table 3. Stage I/II Stage III Stage IV Stage V p
N=20 N=20 N=20 N=20
E/A 0.8 (0.8-1.1) 0.8 (0.7-0.95) 0.9 (0.8-1.2) 0.9 (0.8-1.3) NS
E/E’ 7.4±2.0 8.1±3.9 7.1±3.5 13.6±4.41,3,6 P=0.001
Diastolic dysfunction [%] 81.8 93.3 100.0 94.7 NS
Contractility disorders [%] 33.3 42.9 36.4 78.91,5 P=0.040
Mitral valve fibrosis [%] 81.8 80.0 70.6 90.5 NS
Aortic valve fibrosis [%] 9.1 20.0 23.5 4.8 NS
Mitral valve calcifications [%] 0 0 17.6 28.61 P=0.044
Aortic valve calcifications [%] 0 13.3 23.5 61.92,5 P=0.0008
IM [%] 54.5 50.0 58.8 81.0 NS
IA [%] 10.0 12.5 0 4.8 NS
IT [%] 27.3 25.0 37.5 71.41 P=0.016
1p<0.05; 2p<0.01 vs Stage I; 3p<0.05; 4p<0.01 vs Stage III; 5P<0.05; 6p<0.01 vs Stage IV
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Discussion
This preliminary study analysed the possible markers of
atherosclerotic and calcification processes occurring in
CKD patients and possible novel mechanisms of in-
creased cardiovascular risk in this group of patients.
The results of biochemical parameters analysis (signifi-
cantly lower levels of Na+, haemoglobin and iron, as well
as higher levels of CRP, PO4
− and triglycerides in patients
with CKD stages I-V in comparison with the control
group) are consistent with results of other studies [12,
13] and are associated with kidney damage. Also, signifi-
cantly higher concentrations of urea, creatinine and uric
acid in patients with CKD stages I-V are not surprising,
since these are established markers of kidney function.
This study shows that the prevalence of ventricular
hypertrophy (95.3 %) and diastolic dysfunction (93.2 %)
in CKD patients is high. According to the literature, left
ventricular hypertrophy appears in approximately 40 %
of patients with chronic renal insufficiency, and is even
more frequent (75 %) at the onset of ESRD [14, 15]. Pro-
gressive left ventricular enlargement is considered as the
most typical morphological pattern of dialysis patients
and it is a crucial prognostic factor for cardiovascular
mortality in ESRD patients [16, 17]. Diastolic dysfunc-
tion, which is frequent in chronic kidney disease (CKD)
patients, accounts for 40 %-66 % of cardiovascular com-
plications [18]. However, there is still a controversy con-
cerning which parameter (E/A, E’, E/E’) is of better
predictive and prognostic value for the diagnosis of dia-
stolic dysfunction and the assessment of its clinical out-
comes [19]. It has been suggested that the use of
multiple echocardiographic indices to diagnose and to
grade diastolic dysfunction seems to be the best solution.
This analysis revealed that in patients with CKD stage
V/dialysis the E/E’ ratio was significantly higher than in
other groups (13.6 ± 4.4, p = 0.001) and that in this
group of patients tricuspid insufficiency was significantly
more prevalent (p = 0.016). The results of the de Bie
et al. [20] study confirm that diastolic dysfunction is
highly prevalent among dialysis patients but they imply
that its prevalence in this group of patients might be
underestimated using conventional measurements. The
diagnosis of LV diastolic dysfunction has been demon-
strated to provide independent, prognostic value for
long-term mortality and cardiovascular death in patients
with end-stage renal disease [21]. As shown by Han
et al. [19], the increase in E/E’ (E/E’ > 15) and left atrium
(LA) volume index (LAVI > 32 mL/m2) are significant
risk factors for CV events in incident dialysis patients
with preserved LV systolic function.
Vascular calcification (VC) within the media and in-
tima layers of arteries contributes considerably to the
greater mortality of patients with chronic kidney disease
[22, 23]. This pathological calcification seems to be asso-
ciated with an elevated serum calcium phosphate and
with differentiation of vascular or mesenchymal cells
into osteoblast-like cells [24]. Changes of the mitral ring,
which extend towards valve leaflets, are particularly fre-
quent [25, 26]. In this study mitral valve calcification in
CKD patients was observed, but it was only slightly
more frequent than in the control group. However, pa-
tients with CKD were more likely to have aortic valve
calcification (study group 30.2 % vs. 0 % control group,
p < 0.02). In another study, the joint prevalence of mitral
or aortic valve calcification was 31 % in pre-dialysis pa-
tients, 50 % in dialysis patients and 12 % in control
group (p = 0.001) [27]. In this study, contractile dysfunc-
tion, mitral valve calcification and aortic valve calcifica-
tion in HD patients were significantly more frequent
than in other groups of patients suffering from chronic
kidney disease (p = 0.040; p = 0.044; p = 0.0008, respect-
ively), which is consistent with results obtained in other
Table 4 The results of analysis of selected proteins concentrations
Table 4 Control group Stage I/II Stage III Stage IV Stage V p
N=24 N=20 N=20 N=20 N=20
Fetuin A [ng/ml] 102,9±61,1 110,6±74,7 120,1±82,2 102,1±77,4 125,2±63,3 NS
MMP-2 [ng/ml] 103,0±55,7 161,6±105,7 213,0±187,8 270,9±144,5** 228,5±117,6* P=0,002
MMP-9 [ng/ml] 18,4±5,6 16,9±6,5 17,4±5,9 18,0±6,5 18,0±7,6 NS
TIMP-1 [ng/ml] 23,6±2,9 19,9±2,5** 22,1±2,7 21,4±2,5 21,1±1,9* P=0,002
TIMP-2 [ng/ml] 21,0±2,8 21,8±2,2 22,9±1,4* 21,5±2,0 22,0±1,7 NS
MMP-2/TIMP-2 4,7±2,9 7,4±4,6 9,2±7,9 11,9±6,9** 10,5±5,8* P=0,002
MMP-9/TIMP-1 0,93±0,43 0,80±36 0,77±0,26 0,81±0,39 0,83±0,39 NS
Osteocalcin [ng/ml] 6,2±4,0 7,8±4,5 7,0±3,8 5,0±4,4 3,9±4,1 NS
Osteopontin [ng/ml] 38,0±22,5 11,3±5,1 29,7±33,6 29,8±29,9 28,7±19,7 NS
Osteoprotegerin[pmol/l] 6,0±5,3 4,5±5,6 6,3±5,4 6,4±5,1 8,7±6,1 NS
MGP [ng/ml] 103,7±30,4 105,8±44,4 103,5±29,5 100,7±41,9 88,7±55,0 NS
*p<0.05; **p<0.01 vs control
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studies [27]. Some studies demonstrated that the severity
of vascular and valvular calcification in haemodialysis
patients is associated with the incidence of cardiovascu-
lar complications and predicts cardiovascular mortality
[25, 28]. Due to the fact that high frequency of cardio-
vascular disease cannot be explained only by the
influence of traditional risk factors including smoking,
hypertension, diabetes, disturbed lipid metabolism and
aging there is a need to look for new mechanisms in-
volved in its pathogenesis [22, 29, 30].
According to studies, in comparison to non-uremic
serum, uremic serum increases the mineralization of
vascular smooth muscle cells (VSMCs) and up-regulates
the expression of Cbfa1/Runx2 and osteopontin (OPN),
regardless of the serum P2 concentration [29, 31]. Bone-
associated proteins such as fetuin A, osteoprotegerin
(OPG), osteopontin (OPN) and MGP have been demon-
strated to be expressed in atherosclerotic plaques and to
participate in its calcification, while exogenous osteocal-
cin was shown to inhibit the process of calcification [32].
The level of osteocalcin (which is a non-collagenous,
vitamin K-dependent protein produced by osteoblasts) is
considered to be a non-invasive marker of osteoblast ac-
tivity and bone formation [33]. In this study, no statisti-
cally significant differences in osteocalcin concentration
between the control group and patients with chronic
kidney disease were observed. However, it was found
that the concentration of osteocalcin was highest in pa-
tients with stage I/II CKD and gradually decreased to
reach its lowest value in patients with stage V/dialysis.
Levels of osteocalcin in patients with CKD stage I-II and
III were higher than in patients with higher CKD stages.
Similar results were obtained in the study of Delmas
et al. [34] who observed elevated levels of osteocalcin in
patients with mild or moderate renal impairment. Ac-
cording to them, such results reflect the enhanced bone
metabolism rather than decreased renal filtration.
Vitamin K-dependent MGP (matrix Gla-protein) is an-
other important inhibitor of vascular calcification, which
directly inhibits calcium precipitation and crystallization
in the vessel wall and also plays a role in maintaining a
normal phenotype of VSMCs and in preventing their
differentiation into osteoblasts [29]. Although this study
failed to reveal significant differences in the concentra-
tion of this protein between CKD patients and healthy
volunteers, it was noted that MGP concentration de-
creased with worsening kidney function, which is con-
sistent with other studies demonstrating significantly
lower serum levels of uncarboxylated MGP (ucMGP) in
dialyzed adult compared to healthy controls [35–37].
However, Schurgers et al. [36] observed that plasma
levels of the inactive, dephosphorylated, uncarboxylated
MGP (dp-ucMGP) levels increased progressively in the
setting of CKD. Moreover, they reported an independent
association between higher dp-ucMGP levels and aortic
calcification as well as a limited relationship to overall
mortality risk in CKD patients [38]. Osteoprotegerin de-
ficiency is associated with vascular calcification through
the inhibition of osteoclast differentiation and the modu-
lation of bone resorption [29, 39]. Serum concentrations
Table 5 Multivariate analysis of obtained results
Table 5 p OR 95.0 % CI range
The presence of heart failure
Chronic kidney disease 0,030 4,625 (1,161 - 18,429)
Osteopontin 0,045 0,979 (0.960 - 1,000)
Age 0,010 1,074 (1,017 - 1,135)
(independent of osteocalcin, osteoprotegerin, fetuin, gender)
Age 0,004 1,083 (1,026 - 1,142)
MMP-2 0,048 1,004 (1,000 - 1,009)
(independent of gender, chronic kidney disease, MMP-9, TIMP-1, TIMP-2)
Age 0,001 1,109 (1,046 - 1,176)
Chronic kidney disease 0,038 5,361 (1,098 - 26,176)
(independent of gender, MGP, ANGII, chronic kidney disease)
Age 0,004 1,083 (1,026 - 1,143)
Chronic kidney disease 0,013 7,449 (1,532 - 36,222)
AIP 0,053 8,694 (0,977 - 77,396)
(independent of gender, ABCA1, ABCG1, non-HDL cholesterol, urea)
Phosphates above normal level
Osteoprotegerin 0,025 1,163 (1,019 - 1,328)
(independent of osteocalcin, osteopontin, fetuin, age, gender)
Presence of hypertension
Chronic kidney disease 0,007 8,202 (1,790 - 37,584)
(independent of age, gender, MMP-2, MMP-9, TIMP-1, TIMP-2)
The presence of atherosclerosis
Gender 0,017 0,223 (0,065 - 0,769)
(independent of age, chronic kidney disease, MMP-2, MMP-9, TIMP-1,
TIMP-2)
Gender 0,045 0,301 (0,093 - 0,971)
(independent of age, chronic kidney disease, MGP, GM-CSF, ANGII
Lipid disorders
Non-HDL cholesterol 0,007 1,881 (1,186 - 2,983)
(independent of age, gender, chronic kidney disease, ABCA1, ABCG1,
AIP, urea)
AIP – high risk
TCh 0,000 0,019 0,003 – 0,138
Non-HDL cholesterol 0,000 110,134 11,416 - 1062,535
(independent of age, gender, chronic kidney disease, ABCA1, ABCG1,
urea)
Abbreviations: MMP-2 matrix metalloproteinase 2, MMP-9 matrix
metalloproteinase 9, TIMP-1 & TIMP-2 tissue inhibitor of metalloproteinases-
1&2, MGP matrix Gla protein, AngII angiotensin II, GM-CSF granulocyte-
macrophage colony-stimulating factor, AIP atherogenic index of plasma, TCh
total cholesterol, ABCA1 ATP binding cassette subfamily A member 1, ABCG1
ATP-binding cassette sub-family G member 1
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of osteoprotegerin seems to be a useful biomarker for
early diagnosis of chronic kidney disease-mineral and
bone disorder (CKD-MBD) [40]. In this study, osteopro-
tegerin concentrations in the control and study groups
did not differ significantly. Osteoprotegerin levels were
lowest in subjects with I/II stage CKD and gradually in-
creased to reach its highest values in patients with stage
V/dialysis. Morena et al. [41] also observed that a de-
cline in renal function was associated with a significant
increase in OPG. Omland et al. [42] demonstrated that
raised levels of circulating OPG in patients with chronic
kidney disease are associated with both aortic calcifica-
tion and increased mortality. Moreover, in a study by
Nascimento et al. [43], elevated OPG levels independ-
ently correlated with all-cause mortality and atheroscler-
osis assessed on the basis of increased IMT. However, it
is still not known whether the increased levels of OPG
levels reflects a protective, counter-regulatory effect or is
associated with inflammatory processes which underlies
the development of atherosclerosis [44, 45].
No significant differences in the levels of osteopontin
and fetuin A between the control and study group were
seen in this study. Fetuin A is a calcification inhibitor
and reduced serum levels of this protein are associated
with increased cardiovascular mortality in dialysis pa-
tients [24]. Westenfeld et al. [24] demonstrated that the
co-existence of CKD, atherosclerotic vascular damage,
hyperphosphatemia and fetuin-A deficiency is associated
with significant increases in vascular calcification, almost
exclusively intimal calcification of atheromatous lesions.
Moreover, fetuin A deficiency in HD patients was found
to be a predictor of inflammation-related cardiovascular
and all-cause mortality, respectively [46, 47].
Osteopontin (OPN) has been recently identified as a
component of human atherosclerotic plaque (in symp-
tomatic carotid atherosclerosis [48] and in calcified cor-
onary plaques [49]) implying a role for this protein in
atherogenesis [50]. OPN protein was found to be
abundant at calcification sites in human atherosclerotic
plaques [49] and to be associated with carotid plaque
vulnerability [51, 52], the presence and extent of coron-
ary artery disease [50] in non-renal adult patients and
myocardial remodeling, which might further influence
ventricular function [53]. Barreto et al. [50] demon-
strated elevated plasma OPN levels also in patients with
chronic kidney disease, even at early stages, in compari-
son to healthy volunteers. They also reported that the
positive association between plasma osteopontin level
and clinical outcomes of CKD patients depended on
their inflammatory status [50]. The lack of association
between fetuin A and osteopontin in this study may be
due to the relatively small sample size.
We also analysed the concentration of two matrix me-
talloproteinases (MMPs) and their inhibitors (TIMPs).
Matrix metalloproteinases are endopeptidases respon-
sible for the tissue remodeling and degradation of the
extracellular matrix (ECM). The analysed MMPs −2 and
−9 degrade type IV collagen, which is the main struc-
tural component of basement membrane [54]. Metallo-
proteinases are involved in atherogenesis and over-
expression of MMP-2 and −9 has been observed within
plaques [54, 55]. MMPs are able to damage fibrous cap
of an atherosclerotic plaque thus making it unstable
[56]. Matrix metalloproteinases (MMPs) production
from macrophages could be enhanced by interferon
(IFN)-γ from Th1 lymphocytes. IL-33 within IL-33/ST2
signaling pathway lowers serum levels of IFN-γ and pre-
vents MMPs activation, retarding extracellular matrix
destruction and plaque rupture [57]. Elevated serum
levels of MMP-9 has been observed during the acute
phase of myocardial infarction [58] with its maximum
concentrations in the culprit coronary artery rather than
systemic circulation [59]. In patients with non-ST seg-
ment elevation myocardial infarction (NSTEMI) the
lower serum levels of IL-33 negatively correlated with
MMP-9 (r = −0.461, p < 0.05) levels [56, 60]. Moreover,
Table 6 The relationship between selected protein concentration and other parameters
Table 6. Hypertension ALP ↑ CRP ↑ Fe ↓ ↑ inorganic P ↑ Uric acid ↑ Urea
Fetuin A [ng/ml] 112.1±74.3 168.9±65.74 108.7±74.5 115.6±77.3 106.4±69.2 114.1±83.3 120.7±73.6
MMP-2 [ng/ml] 217.8±150.92 225.4±82.0 229.4±116.15 232.1±158.9 240.2±134.0 264.1±163.81 227.7±132.84
MMP-9 [ng/ml] 18.3±6.5 17.9±7.2 19.0±7.0 17.8±6.3 17.4±6.9 19.6±5.64 18.0±7.0
TIMP-1 [ng/ml] 21.5±2.7 21.1±2.2 21.4±2.2 21.8±2.4 21.3±2.1 20.9±2.54 21.5±2.4
MMP-2/TIMP-2 9.8±6.83 10.4±3.4 10.6±5.64 10.5±6.8 11.2±6.6 11.6±7.41 10.3±6.24
MMP-9/TIMP-1 0.84±0.35 0.86±0.41 0.88±0.39 0.83±0.33 0.82±0.37 0.91±0.316 0.83±0.41
Osteocalcin [ng/ml] 5.9±4.1 3.2±3.2 4.9±4.35 5.0±4.7 4.1±3.64 5.6±3.6 4.9±4.11
Osteopontin [ng/ml] 26.3±26.13 17.6±7.7 25.9±20.9 32.4±31.1 31.4±25.1 26.4±30.0 28.0±23.3
Osteoprotegerin [pmol/l] 7.3±5.81 8.2±4.3 7.2±4.9 7.9±5.84 9.5±6.41 7.4±5.7 7.3±5.6
MGP [ng/ml] 103.7±30.4 62.0±28.44 93.2±44.2 85.8±39.21 97.4±58.6 102.1±38.4 95.7±43.4
1p<0.01; 2p<0.0001; 3p=0.065; 4p<0.05; 5p<0.07; 6p<0.08
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it has been suggested that elevated levels of MMP-2 and
decreased concentration of MMP-9 are associated with
the development of chronic kidney disease [61]. This
study revealed significantly higher levels of MMP-2 in
patients with chronic kidney disease in comparison to
the control group. The lowest concentration of MMP-2
was seen in patients with CKD stage I/II and the highest
in patients with stage IV and in those on dialysis. Our
results are in accordance with the study of Pawlak et al.
[62] who observed increased serum MMP-2 and also −9
in HD patients with a history of cardiovascular disease
in comparison to patients without such history and con-
trol group. Chen et al. [63] demonstrated the role of
MMP-2 and MMP-9 in arterial calcification. Moreover,
they observed increased expression of MMP-2 and
MMP-9 in the aorta of rats with progressive CKD as
well as elevated serum activity of MMP-2. The over-
expression of these two metalloproteinases was accom-
panied by the increased expression of transcription fac-
tor RUNX-2, which is thought to play an important role
in the osteochondrocytic differentiation of VSMC and
further in calcification [64].
Significant differences in concentration were also ob-
served in metalloproteinase inhibitor TIMP-1. The high-
est concentration was observed in the control group,
and the lowest in the group of patients with stage I/II
CKD and in all CKD patients’ levels of TIMP-1 was
lower than in the control group. Similarly to the results
obtained by Musiał et al. [65] in the study of children
with CKD, in this analysis, serum TIMP-1 concentra-
tions increased in the late stages (II, IV) of renal failure
which might be an anti-fibrotic response to extracellular
matrix accumulation [66]. Some studies demonstrated
that abundant TIMP-1 expression in the kidneys posi-
tively correlated with the extent of fibrosis [67–69].
However, in this study in all patients with CKD, TIMP-1
concentration was lower than in control group. Statisti-
cally significant results were found also for the MMP-2/
TIMP-2 ratio, with the lowest values in the control
group and the highest in patients with stage IV chronic
kidney disease as well as in patients with stage V CKD
and on dialysis. It has been suggested that CKD-
associated MMP/TIMP imbalance disrupts the integrity
of the extracellular matrix and leads to tissue remodel-
ing, cells damage and matrix accumulation and further
to atherosclerosis, renal fibrosis and enhanced cell mi-
gration to sites of inflammation [70]. Also, Rysz et al.
[71] observed increased MMP-2/TIMP-2 ratio in HD
patients compared with patients with CKD and controls.
In contrast, in the study of Musiał et al. [70], MMP-2/
TIMP-2 ratio was higher in CKD stages 2–3 vs. controls
and thus they suggested that disturbances in MMP/
TIMP balance are noticeable in early CKD, but as
chronic kidney disease progresses it becomes corrected
and stabilized. The discrepancies between studies results
may be explained by differences in ethnicity of analysed
populations, age, and CKD aetiology. The results of
matrix metalloproteinases and their inhibitors analysis
can be treated with caution due to the fact that their
concentration may be influenced by used medications.
According to Tayebjee MH [72] circulating MMP-9
levels are decreased while circulating TIMP-1 levels are
increased after antihypertensive treatment. Moreover, it
has been shown that nitroglycerin increases the expres-
sion and the activity of MMP-2, MMP-7 and MMP-9,
and reduces TIMP-1 levels [73]. Medications such as
calcium channel blockers (amlodipine, diltiazem), angio-
tensin II and angiotensin converting enzyme (ACE) in-
hibitors affects the activity of MMPs, not affecting its
expression [74–76].
Multivariable analysis of comorbidities and protein
concentrations demonstrated that the presence of heart
failure was associated with the presence of chronic kid-
ney disease. Also in the study of Heywood et al. [77]
there was a relationship between the prevalence of cor-
onary artery disease and worsening kidney function.
However, due to the fact that heart failure and CKD
share common risk factors it is often difficult to assess
whether CKD in heart failure is prevalent or incident
CKD, or rather a manifestation of cardio-renal syndrome
[78, 79]. This multivariable analysis also revealed associ-
ation between heart failure and osteopontin level. Also
López et al. [80] found that plasma OPN was abnormally
increased in patients with HF of hypertensive origin.
Moreover, multivariable analysis including demographic,
clinical and biochemical parameters indicated that osteo-
pontin could be an independent predictor of death (haz-
ard ratio 2.3, 95 % confidence interval 1.4 to 3.5, P <
0.001) and that it might be useful as a novel prognostic
biomarker in patients with chronic heart failure [81].
In this study, heart failure was also associated with
MMP-2, GM-CSF and atherosclerotic index of plasma
(AIP). The association between MMPs and heart failure
may be due the fact that metalloproteinases influences
the process of atherosclerotic lesion formation due to in-
tensified migration and proliferation of vascular smooth
muscle cells in the intimal space, as well as the degrad-
ation of the fibrous cap of vulnerable atherosclerotic le-
sions [82]. According to Dobiasova et al. [83]
atherogenic index plasma (AIP) (which is the logarithm
of the plasma triglyceride level to high-density lipopro-
tein cholesterol) correlates with LDL particle size. A
strong relationship between increased AIP high levels of
small-dense LDL particles was demonstrated. The study
of haemodialysis patients revealed that although in this
group LDL levels were lower than in the controls, AIP
ratio was higher, which may suggest that the size of
LDL-c particles is of higher importance than their
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concentration in rapidly progressing atherosclerosis in
ESRD. AIP was also suggested to be a subclinical athero-
sclerosis marker [84].
Moreover, in our multivariate analysis there was also
relationship between phosphates (Pi) above normal level
and osteoprotegerin (OPG). The study of paediatric pa-
tients with chronic kidney disease [85] provided plaus-
ible explanation for the association observed in our
study. Siomou et al. [85] demonstrated a positive correl-
ation between OPG levels and fibroblast growth factor-
23 (FGF-23) levels which was not independent of serum
Pi concentrations, which as they suggested may indicates
possible compensatory reaction of OPG synthesis in re-
sponse to increased Pi levels. In case of elevated serum
phosphate levels, FGF-23 is secreted from the bone and
it acts on the kidney to induce phosphaturia in order to
maintain phosphate homeostasis [85].
Additionally, in our study the presence of hypertension
was associated with chronic kidney disease, while lipid
disorders with non-HDL cholesterol, AIP (high risk) and
total cholesterol.
Both associations are not a new finding. It is com-
monly known that the relationship between hyperten-
sion and CKD is of cyclic nature. On the one hand,
uncontrolled hypertension is an important risk factor for
the development of CKD and is the second leading cause
of ESRD [5], but on the other hand chronic kidney dis-
ease is one of the most common causes of secondary
hypertension with prevalence increasing progressively
with the severity of CKD [86]. Also the relationship be-
tween lipid disorders and non-HDL cholesterol, total
cholesterol and AIP (high risk) is not surprising. Numer-
ous studies indicate abnormalities in lipid metabolism in
patients with all stages of chronic kidney disease (CKD)
[87–89]. These abnormalities refer to all lipoprotein
classes and depend on the degree of renal impairment,
the aetiology of primary disease and dialysis method
[90]. In CKD and dialysis patients, hypertriglyceridemia
seems to be the most common form of dyslipidemia.
[91]. All lipid abnormalities observed in chronic kidney
disease including also diminished serum apoA-1 and
high-density lipoprotein (HDL) concentrations, defective
HDL maturation and its impaired antioxidant, anti-
inflammatory and reverse cholesterol transport proper-
ties as well as compromised clearance of very low-
density lipoprotein and chylomicrons in addition to oxi-
dative stress are associated with increased risk of athero-
sclerosis in this group of patients [92]. Thus, it is not
surprising that high risk AIP was observed in CKD pa-
tients in this study. Since AIP, as it was mentioned
above, is the logarithm of plasma triglycerides to high-
density lipoprotein cholesterol, its relationship with lipid
disorders is not surprising. Moreover, it should be kept
in mind that the size of LDL-c particles (and perhaps
HDL particles) may be more important than their
concentration.
We also analysed the relationship between protein
concentration and various biochemical markers. An as-
sociation between higher fetuin A concentration and in-
creased level of alkaline phosphatase (ALP) was noted.
We did not find any study observing a similar correl-
ation. Serum ALP is a marker of bone turnover used to
monitor the metabolic bone disease associated with
renal insufficiency [93]. Experimental studies revealed
that alkaline phosphatase might promote vascular calcifi-
cation [94]. A high level of fetuin A coexisting with in-
creased concentration of ALP may act as a defence
mechanism against calcification. However, fetuin-A-
mediated inhibition is overwhelmed in CKD and espe-
cially in CKD/HD [95]. Our study also revealed an asso-
ciations between lower levels of osteocalcin and both
elevated serum inorganic P and increased levels of urea
as well as between higher levels of osteoprotegerin and
increased concentrations of inorganic P. In patients with
CKD, it is well established that hyperphosphatemia is as-
sociated with the development of vascular calcification
[27, 62, 96]. In the past, vascular calcification induced by
high serum phosphate was explained by simply exceed-
ing (Ca2-P
2) solubility, resulting in the precipitation of
calcium phosphate. However, recent studies have dem-
onstrated that high extracellular phosphate levels induce
the transformation of VSMCs into osteoblast-like cells,
which suggests that vascular calcification is an active
process. Moreover, elevated extracellular phosphate
levels are associated with the induction of Cbfa1/Runx2,
a specific transcription factor for osteoblastic differenti-
ation and the increase in bone-associated proteins such
as osteocalcin, osteopontin and alkaline phosphatase
(ALP) [27, 97, 98].
In this study, also a correlation between higher levels
of metalloproteinase MMP-2 as well as higher values of
MMP-2/TIMP-2 ratio and the prevalence of arterial
hypertension was observed. The study of Chung et al.
[64] demonstrated a correlation of MMP-2 with arterial
stiffness in CKD patients. Moreover, Odenbach et al.
showed that MMP-2 inhibition attenuated Ang II-
induced hypertension [98]. According to Pawlak et al.
[99], MMP-2/TIMP-2 ratio was higher in peritoneal dia-
lysis (CAPD) patients with cardiovascular disease than
in patients without CAD and healthy controls, and it
was associated with quinolinic acid (QA) levels and in-
creased oxidative status, suggesting the connection be-
tween kynurenine (KYN) pathway activation, arterial
remodelling and CVD prevalence in uremic patients. Fi-
nally, in our study a statistically significant correlation
between MMP-2/TIMP-2 and elevated values of CRP
was seen. We found no studies confirming this correl-
ation. However, in a study by Rysz et al. CRP was
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positively correlated with MMP-9 and MMP-9/TIMP-1
ratio in haemodialysis patients and patients with CKD
[69].
Conclusions
This study shows that the prevalence of ventricular
hypertrophy and diastolic dysfunction in CKD patients
is high. Moreover, in patients with CKD stage V/dialysis
the E/E’ ratio was significantly higher than in other
groups and tricuspid insufficiency was significantly more
prevalent. Additionally, contractile dysfunction, mitral
valve calcification and aortic valve calcification in HD
patients were significantly more frequent than in other
groups of patients suffering from chronic kidney disease.
In this study, significantly increased levels of MMP-2,
MMP-2/TIMP-2 ratio and lower levels of TIMP-1 were
observed, suggesting that these factors may be involved
in the pathogenesis of atherosclerosis in patients with
CKD. Analysis of the levels of proteins associated with
bone metabolism did not show statistically significant
differences in the level of the analysed proteins between
the healthy group and patients with chronic renal failure.
Lack of significant correlations between bone-associated
proteins could be due to the fairly small size of groups.
In patients with CKD hypertrophy and calcification of
the aortic valve were observed more frequently, which
may suggest the reasons for increased cardiovascular risk
in CKD patients.
Limitations
Our study has some limitations. The number of partici-
pants included to the study is relatively small (80 pa-
tients with CKD and 24 healthy volunteers) due to the
fact that it was a preliminary study. In this study, there
may be a selection bias toward patients with associated
disorders that might influence laboratory results due to
the fact that patients for both control and study group
were recruited among hospitalized persons. Study and
control groups differ in age due to the difficulty to find
healthy people aged 60–70 years to match study group.
There are also differences in other demographic data
such as sex, diabetes mellitus and hypertension between
groups. Another limitation of this study is its cross-
sectional design.
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